Show Cart
PipelineReview.com
Home
My cart / Checkout
Contact Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
Antibodies
DNA, RNA & Cells
Protein & Peptides
Small Molecules
Vaccines
More News
Reports
All Products
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells & NK Cells
Immuno-Oncology
mRNA Vaccines & Therapeutics
Pipeline Database
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Proteins & Peptides
Vaccines
FREE reports
Offers
Press Room
About Us
Home
News Channels
Antibodies
Antibodies
28 Oct 2018
New Stairway Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)
26 Oct 2018
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
26 Oct 2018
Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Soli
26 Oct 2018
Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
24 Oct 2018
NextCure Initiates Clinical Development for NC318, a Siglec-15 Targeting Antibody, for Solid Tumors
24 Oct 2018
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
24 Oct 2018
KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development
24 Oct 2018
New Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
24 Oct 2018
NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
24 Oct 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
24 Oct 2018
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
23 Oct 2018
Alpine Immune Sciences’ Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation
23 Oct 2018
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
23 Oct 2018
Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC
23 Oct 2018
ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
23 Oct 2018
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma
23 Oct 2018
Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer
23 Oct 2018
Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology
23 Oct 2018
Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress
23 Oct 2018
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
23 Oct 2018
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
22 Oct 2018
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
22 Oct 2018
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma
22 Oct 2018
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
22 Oct 2018
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
Page 10 of 242
Start
Prev
5
6
7
8
9
10
11
12
13
14
Next
End
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
Currencies
Australian dollar $
British pound £
Canadian dollar $
Danish krone kr
Euro €
Japanese yen ¥
Swedish krona kr
Swiss franc CHF
United States dollar $
Shopping cart
Cart empty
Please wait
Latest report
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018
Featured Products
Report Package: TCR-Based Antibody and T-Cell Immunotherapy
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
Latest Target Pipeline
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
La Merie Biologics
FREE Weekly News Bulletin
Sign Up
2017 Sales of
Antibodies & Proteins
Get it now
New Product Alert
For La Merie Publishing
Sign Up
Top